abacavir Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals carbocyclic nucleosides 34 136470-78-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • 1592U89
  • abacavir
  • abacavir sulfate
  • ziagen
  • abacavir succinate
a carbocyclic nucleoside with potent selective anti-HIV activity; structure given in first source
  • Molecular weight: 286.34
  • Formula: C14H18N6O
  • CLOGP: 0.81
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 101.88
  • ALOGS: -2.37
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 77 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1.20 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 29.93 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 83 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.84 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 13 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.50 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 8, 1999 EMA
Dec. 17, 1998 FDA VIIV HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Exposure during pregnancy 757.63 21.08 418 11213 124442 53212993
Abortion spontaneous 428.65 21.08 207 11424 46428 53291007
Virologic failure 389.82 21.08 92 11539 2172 53335263
Foetal exposure during pregnancy 370.85 21.08 171 11460 34544 53302891
Viral mutation identified 366.10 21.08 86 11545 1988 53335447
Live birth 273.04 21.08 108 11523 14951 53322484
Pathogen resistance 259.86 21.08 84 11547 6476 53330959
Immune reconstitution inflammatory syndrome 234.11 21.08 77 11554 6269 53331166
Lipodystrophy acquired 217.10 21.08 54 11577 1596 53335839
Drug resistance 205.71 21.08 96 11535 19866 53317569
Maternal exposure during pregnancy 184.58 21.08 197 11434 155442 53181993
Premature baby 178.90 21.08 87 11544 19714 53317721
Hypomania 171.10 21.08 57 11574 4825 53332610
Jaundice cholestatic 167.96 21.08 58 11573 5476 53331959
Foetal growth restriction 164.20 21.08 61 11570 7113 53330322
Abortion induced 153.05 21.08 65 11566 10761 53326674
Hepatotoxicity 148.22 21.08 86 11545 27794 53309641
Treatment noncompliance 142.26 21.08 89 11542 32946 53304489
Schizophrenia 129.83 21.08 57 11574 10222 53327213
Foetal death 128.41 21.08 55 11576 9292 53328143
Blood HIV RNA increased 124.45 21.08 30 11601 775 53336660
Stillbirth 113.59 21.08 46 11585 6751 53330684
Caesarean section 104.35 21.08 58 11573 17262 53320173
Psychotic disorder 98.22 21.08 63 11568 24322 53313113
Blood bilirubin increased 93.86 21.08 71 11560 35659 53301776
Pregnancy 88.22 21.08 65 11566 31376 53306059
Hyperbilirubinaemia 86.23 21.08 44 11587 11025 53326410
Acoustic stimulation tests abnormal 85.54 21.08 16 11615 113 53337322
Supernumerary nipple 84.13 21.08 15 11616 78 53337357
Drug interaction 79.19 21.08 158 11473 219171 53118264
Congenital naevus 75.83 21.08 16 11615 221 53337214
CD4 lymphocytes decreased 72.32 21.08 23 11608 1678 53335757
Low set ears 71.60 21.08 16 11615 293 53337142
Premature delivery 68.83 21.08 52 11579 26052 53311383
Premature labour 67.96 21.08 39 11592 12323 53325112
Drug ineffective 64.08 21.08 51 11580 817194 52520241
Cholelithiasis 63.33 21.08 60 11571 40904 53296531
Viral load increased 62.94 21.08 20 11611 1455 53335980
Drug reaction with eosinophilia and systemic symptoms 60.40 21.08 53 11578 32747 53304688
Fall 59.63 21.08 5 11626 358435 52979000
HIV infection 56.47 21.08 15 11616 577 53336858
HIV-associated neurocognitive disorder 55.89 21.08 12 11619 181 53337254
Pain 50.87 21.08 33 11598 588365 52749070
Ectopic pregnancy 50.50 21.08 20 11611 2767 53334668
Mitochondrial cytopathy 49.09 21.08 12 11619 329 53337106
Placenta praevia 48.49 21.08 15 11616 999 53336436
Spina bifida 47.93 21.08 14 11617 766 53336669
Mitochondrial toxicity 47.31 21.08 12 11619 384 53337051
Trisomy 21 47.01 21.08 12 11619 394 53337041
Oligohydramnios 46.87 21.08 24 11607 6052 53331383
Gastroschisis 46.68 21.08 11 11620 257 53337178
Fatigue 46.26 21.08 55 11576 730451 52606984
Hepatic enzyme increased 44.35 21.08 90 11541 126105 53211330
Fanconi syndrome acquired 43.43 21.08 14 11617 1067 53336368
Renal failure 42.24 21.08 85 11546 118367 53219068
Pre-eclampsia 41.53 21.08 25 11606 8622 53328813
Twin pregnancy 41.44 21.08 14 11617 1235 53336200
Placental insufficiency 40.11 21.08 14 11617 1362 53336073
Hepatocellular injury 39.04 21.08 40 11591 29946 53307489
Off label use 38.74 21.08 28 11603 472184 52865251
Cholestasis of pregnancy 37.95 21.08 13 11618 1196 53336239
Patent ductus arteriosus 36.88 21.08 18 11613 4100 53333335
Infertility 36.35 21.08 11 11620 680 53336755
Left ventricular dilatation 36.21 21.08 10 11621 446 53336989
Low birth weight baby 34.85 21.08 20 11611 6317 53331118
Ovarian failure 34.71 21.08 12 11619 1135 53336300
Pain in extremity 33.99 21.08 10 11621 285040 53052395
Peripheral swelling 33.89 21.08 3 11628 206105 53131330
Renal colic 33.00 21.08 12 11619 1315 53336120
Normal newborn 32.54 21.08 20 11611 7159 53330276
Astrocytoma malignant 31.88 21.08 6 11625 44 53337391
Jaundice 31.67 21.08 36 11595 30277 53307158
Ultrasound scan abnormal 30.93 21.08 8 11623 277 53337158
Antiviral drug level below therapeutic 30.89 21.08 6 11625 53 53337382
Microcephaly 30.32 21.08 10 11621 819 53336616
Polyhydramnios 30.24 21.08 13 11618 2212 53335223
Arthralgia 30.06 21.08 31 11600 439752 52897683
Product substitution issue 29.93 21.08 26 11605 15840 53321595
Lipoatrophy 29.37 21.08 8 11623 339 53337096
Drug-induced liver injury 29.33 21.08 34 11597 29199 53308236
Eosinophilia 28.75 21.08 29 11602 21306 53316129
Congenital hydrocephalus 28.56 21.08 7 11624 194 53337241
Renal tubular dysfunction 28.28 21.08 8 11623 390 53337045
Dermatitis exfoliative generalised 27.68 21.08 14 11617 3441 53333994
Proteinuria 27.03 21.08 26 11605 18042 53319393
Breast disorder 26.69 21.08 12 11619 2272 53335163
Mental disability 26.54 21.08 6 11625 116 53337319
Nasopharyngitis 26.35 21.08 5 11626 192290 53145145
Central nervous system lesion 26.23 21.08 20 11611 10142 53327293
Hepatic necrosis 26.01 21.08 16 11615 5734 53331701
Vomiting 25.90 21.08 191 11440 496948 52840487
Bronchopulmonary dysplasia 25.60 21.08 7 11624 301 53337134
Cervix operation 25.33 21.08 4 11627 8 53337427
Genotype drug resistance test positive 25.25 21.08 8 11623 576 53336859
Pleocytosis 24.98 21.08 8 11623 597 53336838
Retroplacental haematoma 24.92 21.08 6 11625 154 53337281
Viral load abnormal 24.18 21.08 4 11627 12 53337423
Pubertal failure 23.94 21.08 4 11627 13 53337422
Paraparesis 23.90 21.08 11 11620 2199 53335236
Small for dates baby 23.78 21.08 13 11618 3739 53333696
Alpha 1 foetoprotein abnormal 23.70 21.08 5 11626 69 53337366
Maxillonasal dysplasia 23.50 21.08 4 11627 15 53337420
Ocular icterus 23.38 21.08 13 11618 3866 53333569
HIV wasting syndrome 23.29 21.08 4 11627 16 53337419
Product size issue 23.18 21.08 7 11624 430 53337005
Acute hepatic failure 23.03 21.08 23 11608 16697 53320738
Insulin resistance 23.01 21.08 8 11623 769 53336666
Premature rupture of membranes 22.99 21.08 14 11617 4926 53332509
Glycosuria 22.89 21.08 9 11622 1221 53336214
Behaviour disorder 22.60 21.08 11 11620 2489 53334946
Infection 22.51 21.08 5 11626 172200 53165235
Swelling 22.23 21.08 7 11624 191098 53146337
Portal vein thrombosis 22.12 21.08 11 11620 2608 53334827
Aqueductal stenosis 21.95 21.08 4 11627 24 53337411
Hemiataxia 21.95 21.08 4 11627 24 53337411
Foetal heart rate disorder 21.86 21.08 5 11626 102 53337333
Generalised anxiety disorder 21.77 21.08 10 11621 1990 53335445
CSF HIV escape syndrome 21.50 21.08 5 11626 110 53337325
Delayed puberty 21.25 21.08 5 11626 116 53337319
Renal tubular disorder 21.19 21.08 11 11620 2852 53334583
Amenorrhoea 21.11 21.08 17 11614 9332 53328103

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Immune reconstitution inflammatory syndrome 619.96 13.44 243 24298 9316 32479669
Lipodystrophy acquired 599.34 13.44 186 24355 3496 32485489
Virologic failure 511.65 13.44 166 24375 3621 32485364
Mitochondrial toxicity 329.84 13.44 109 24432 2521 32486464
Viral mutation identified 318.97 13.44 110 24431 2909 32486076
Progressive external ophthalmoplegia 298.66 13.44 86 24455 1232 32487753
Foetal exposure during pregnancy 222.41 13.44 210 24331 41091 32447894
Pathogen resistance 192.18 13.44 108 24433 9402 32479583
Eyelid ptosis 190.52 13.44 90 24451 5452 32483533
Blood HIV RNA increased 178.90 13.44 61 24480 1556 32487429
Syphilis 135.06 13.44 39 24502 564 32488421
HIV infection 128.40 13.44 50 24491 1876 32487109
Diplopia 121.32 13.44 95 24446 14417 32474568
Polydactyly 118.57 13.44 42 24499 1203 32487782
Drug resistance 108.92 13.44 109 24432 22856 32466129
Lipoatrophy 101.67 13.44 32 24509 629 32488356
Dyslipidaemia 96.98 13.44 62 24479 6821 32482164
Fanconi syndrome acquired 94.83 13.44 42 24499 2188 32486797
Drug interaction 92.61 13.44 367 24174 217818 32271167
Nephrolithiasis 89.84 13.44 107 24434 27247 32461738
Viral load increased 83.90 13.44 43 24498 3107 32485878
Hypertriglyceridaemia 81.47 13.44 61 24480 8658 32480327
Renal impairment 80.34 13.44 199 24342 91773 32397212
HIV-associated neurocognitive disorder 77.32 13.44 23 24518 371 32488614
Hyperbilirubinaemia 76.52 13.44 80 24461 17650 32471335
Hyperlipidaemia 76.50 13.44 73 24468 14438 32474547
Off label use 71.15 13.44 76 24465 306244 32182741
Ophthalmoplegia 70.42 13.44 30 24511 1421 32487564
Osteonecrosis 68.18 13.44 73 24468 16549 32472436
Renal tubular disorder 66.28 13.44 44 24497 5158 32483827
Hepatitis C 65.62 13.44 65 24476 13453 32475532
Nephropathy toxic 62.79 13.44 60 24481 11886 32477099
Extraocular muscle paresis 62.12 13.44 21 24520 521 32488464
Exposure during pregnancy 57.54 13.44 51 24490 9178 32479807
Fall 57.30 13.44 39 24502 196162 32292823
Drug ineffective 55.11 13.44 131 24410 383346 32105639
Mycobacterium avium complex infection 53.21 13.44 31 24510 2886 32486099
Treatment noncompliance 52.16 13.44 82 24459 27120 32461865
Pneumonia 52.11 13.44 120 24421 355132 32133853
Fanconi syndrome 51.84 13.44 26 24515 1794 32487191
CSF HIV escape syndrome 51.58 13.44 14 24527 159 32488826
Hypotension 49.67 13.44 54 24487 216056 32272929
Cachexia 47.77 13.44 41 24500 7068 32481917
Meningitis cryptococcal 47.10 13.44 26 24515 2183 32486802
Kaposi's sarcoma 45.89 13.44 20 24521 1002 32487983
Anal cancer 45.74 13.44 16 24525 441 32488544
White matter lesion 45.24 13.44 18 24523 715 32488270
Cytomegalovirus chorioretinitis 44.69 13.44 30 24511 3582 32485403
Pyrexia 44.36 13.44 401 24140 319567 32169418
Mitochondrial cytopathy 43.85 13.44 13 24528 207 32488778
Lactic acidosis 43.35 13.44 85 24456 33451 32455534
Mitochondrial myopathy 43.34 13.44 13 24528 216 32488769
Hyperlactacidaemia 41.60 13.44 27 24514 3047 32485938
Death 41.56 13.44 149 24392 382368 32106617
Multiple-drug resistance 41.15 13.44 29 24512 3746 32485239
Jaundice 39.89 13.44 83 24458 34075 32454910
Blood triglycerides increased 39.68 13.44 52 24489 14567 32474418
Oesophageal candidiasis 39.28 13.44 30 24511 4384 32484601
CD4 lymphocytes decreased 39.22 13.44 23 24518 2167 32486818
Retinal toxicity 38.68 13.44 14 24527 427 32488558
Premature baby 37.14 13.44 57 24484 18461 32470524
Atrial fibrillation 37.07 13.44 21 24520 116683 32372302
Proteinuria 37.05 13.44 55 24486 17300 32471685
HIV associated nephropathy 36.97 13.44 13 24528 364 32488621
Acquired immunodeficiency syndrome 36.81 13.44 14 24527 492 32488493
Oral candidiasis 36.14 13.44 45 24496 11982 32477003
Febrile neutropenia 34.55 13.44 24 24517 119542 32369443
Tubulointerstitial nephritis 33.42 13.44 56 24485 19521 32469464
Amniotic band syndrome 33.40 13.44 7 24534 22 32488963
Hepatotoxicity 32.59 13.44 55 24486 19282 32469703
Diabetes mellitus 32.49 13.44 91 24450 45082 32443903
Progressive multifocal leukoencephalopathy 32.46 13.44 38 24503 9493 32479492
Calculus urinary 32.44 13.44 17 24524 1286 32487699
Taeniasis 30.86 13.44 8 24533 75 32488910
Anogenital warts 30.59 13.44 13 24528 612 32488373
Blood pressure increased 30.30 13.44 11 24530 79343 32409642
Drug-induced liver injury 29.90 13.44 60 24481 24003 32464982
Osteoporosis 29.51 13.44 41 24500 12141 32476844
Renal colic 29.41 13.44 18 24523 1833 32487152
Drug abuse 29.19 13.44 12 24529 80231 32408754
Trisomy 21 29.04 13.44 12 24529 526 32488459
Facial wasting 28.88 13.44 9 24532 171 32488814
HIV viraemia 28.49 13.44 8 24533 104 32488881
Dyspnoea 28.43 13.44 159 24382 361886 32127099
Myocardial infarction 28.40 13.44 177 24364 125499 32363486
Tuberculosis 28.40 13.44 34 24507 8695 32480290
Malignant neoplasm progression 28.13 13.44 12 24529 78484 32410501
Liver disorder 28.11 13.44 69 24472 31585 32457400
Renal failure 27.70 13.44 185 24356 134293 32354692
Hypercholesterolaemia 27.50 13.44 32 24509 7942 32481043
Constipation 27.44 13.44 33 24508 126340 32362645
Primary syphilis 27.31 13.44 6 24535 25 32488960
Renal disorder 26.87 13.44 59 24482 25124 32463861
Acute myocardial infarction 26.75 13.44 97 24444 55052 32433933
Blood lactic acid increased 26.48 13.44 28 24513 6253 32482732
Nervous system disorder 26.43 13.44 42 24499 14007 32474978
Immune reconstitution inflammatory syndrome associated tuberculosis 26.37 13.44 11 24530 494 32488491
Enterovirus infection 26.31 13.44 12 24529 670 32488315
Oesophageal atresia 26.25 13.44 11 24530 500 32488485
Chronic hepatitis C 26.22 13.44 11 24530 501 32488484
Hyperplasia adrenal 26.18 13.44 5 24536 8 32488977
Completed suicide 26.15 13.44 19 24522 92498 32396487
Drug reaction with eosinophilia and systemic symptoms 25.92 13.44 68 24473 32417 32456568
Glycosuria 25.68 13.44 15 24526 1403 32487582
Human immunodeficiency virus transmission 25.49 13.44 6 24535 36 32488949
Trimethylaminuria 25.46 13.44 5 24536 10 32488975
Bone metabolism disorder 24.95 13.44 9 24532 272 32488713
Bacterial pyelonephritis 24.95 13.44 9 24532 272 32488713
Pharyngitis 24.91 13.44 30 24511 7720 32481265
Renal hypoplasia 24.86 13.44 7 24534 92 32488893
Venolymphatic malformation 24.82 13.44 6 24535 41 32488944
Hypermetabolism 24.66 13.44 8 24533 174 32488811
Product use in unapproved indication 24.53 13.44 18 24523 87186 32401799
Portal hypertension 24.42 13.44 22 24519 4042 32484943
Cerebral toxoplasmosis 24.25 13.44 15 24526 1557 32487428
Lymphoma 24.17 13.44 35 24506 10765 32478220
Lymphadenopathy 24.01 13.44 59 24482 27023 32461962
HIV peripheral neuropathy 23.99 13.44 6 24535 48 32488937
Encephalitis 23.85 13.44 28 24513 7016 32481969
Pain 23.82 13.44 68 24473 187488 32301497
Hemivertebra 23.76 13.44 7 24534 109 32488876
Hyperuricaemia 23.72 13.44 30 24511 8111 32480874
Small for dates baby 23.67 13.44 20 24521 3373 32485612
Neonatal asphyxia 23.51 13.44 9 24532 322 32488663
Hepatic cirrhosis 23.43 13.44 44 24497 16765 32472220
Myalgia 23.33 13.44 122 24419 81108 32407877
Cardiac failure congestive 23.24 13.44 18 24523 84834 32404151
Hepatosplenomegaly 23.20 13.44 21 24520 3882 32485103
Disease progression 23.07 13.44 19 24522 86843 32402142
Drug level decreased 22.45 13.44 26 24515 6420 32482565
Alpha 1 foetoprotein increased 22.43 13.44 11 24530 723 32488262
Pneumocystis jirovecii pneumonia 22.19 13.44 46 24495 18824 32470161
Confusional state 21.99 13.44 47 24494 143068 32345917
Intentional product use issue 21.79 13.44 3 24538 42208 32446777
Oropharyngeal candidiasis 21.56 13.44 11 24530 787 32488198
Choroiditis 20.97 13.44 12 24529 1080 32487905
Hepatomegaly 20.70 13.44 32 24509 10425 32478560
Crystal urine 20.63 13.44 6 24535 89 32488896
Hepatic fibrosis 20.59 13.44 19 24522 3599 32485386
Periarthritis 20.40 13.44 12 24529 1137 32487848
Fracture malunion 20.37 13.44 4 24537 8 32488977
Loss of anatomical alignment after fracture reduction 20.37 13.44 4 24537 8 32488977
Subchondral insufficiency fracture 20.37 13.44 4 24537 8 32488977
Haemophilic arthropathy 20.36 13.44 7 24534 183 32488802
Hypersensitivity 20.35 13.44 92 24449 57666 32431319
Blood bilirubin increased 20.33 13.44 70 24471 38714 32450271
Genotype drug resistance test positive 20.15 13.44 14 24527 1767 32487218
Lipohypertrophy 20.05 13.44 8 24533 320 32488665
Lymphadenitis 19.91 13.44 14 24527 1801 32487184
Hepatitis A 19.91 13.44 9 24532 492 32488493
Sepsis 19.85 13.44 58 24483 158776 32330209
Blood creatinine increased 19.62 13.44 132 24409 96000 32392985
Peripheral swelling 19.36 13.44 14 24527 68331 32420654
Hepatitis 19.31 13.44 50 24491 23643 32465342
Skin candida 19.20 13.44 9 24532 535 32488450
Neuropsychiatric symptoms 19.15 13.44 9 24532 538 32488447
Syncope 19.06 13.44 24 24517 90100 32398885
Endocardial fibroelastosis 18.98 13.44 4 24537 13 32488972
Musculoskeletal toxicity 18.87 13.44 6 24535 122 32488863
Pulmonary tuberculosis 18.86 13.44 21 24520 4968 32484017
Blood insulin increased 18.79 13.44 8 24533 378 32488607
Hypophosphataemia 18.76 13.44 28 24513 8847 32480138
Herpes virus infection 18.62 13.44 16 24525 2762 32486223
Hepatic function abnormal 18.56 13.44 75 24466 44765 32444220
Infection 18.51 13.44 22 24519 84693 32404292
Rash 18.47 13.44 240 24301 209093 32279892
Pulmonary sequestration 18.40 13.44 5 24536 57 32488928
Insomnia 18.26 13.44 134 24407 100214 32388771
Cell death 18.06 13.44 15 24526 2471 32486514
CD4 lymphocytes increased 17.71 13.44 7 24534 273 32488712
Neurosyphilis 17.66 13.44 5 24536 67 32488918
Coccidioidomycosis 17.34 13.44 9 24532 667 32488318
Hepatic enzyme decreased 17.27 13.44 5 24536 73 32488912
Blood uric acid increased 17.18 13.44 23 24518 6576 32482409
Cushingoid 17.11 13.44 15 24526 2659 32486326
Post transplant distal limb syndrome 16.98 13.44 7 24534 305 32488680
Neonatal disorder 16.96 13.44 10 24531 951 32488034
Erythema elevatum diutinum 16.85 13.44 4 24537 25 32488960
Varices oesophageal 16.65 13.44 17 24524 3644 32485341
Chronic obstructive pulmonary disease 16.61 13.44 8 24533 48745 32440240
Psoriasis 16.60 13.44 7 24534 46116 32442869
Biliary colic 16.49 13.44 10 24531 1001 32487984
Heart transplant rejection 16.48 13.44 11 24530 1300 32487685
Polyneuropathy 16.47 13.44 33 24508 13182 32475803
Posterior cortical atrophy 16.46 13.44 4 24537 28 32488957
Epistaxis 16.40 13.44 11 24530 55844 32433141
Transplant rejection 16.27 13.44 28 24513 9971 32479014
Pancreatic failure 16.05 13.44 9 24532 779 32488206
Hallucination 15.94 13.44 10 24531 52609 32436376
Transaminases increased 15.67 13.44 48 24493 24980 32464005
Splenomegaly 15.53 13.44 34 24507 14443 32474542
Joint swelling 15.44 13.44 10 24531 51725 32437260
Long QT syndrome 15.33 13.44 14 24527 2617 32486368
Congenital naevus 15.29 13.44 4 24537 39 32488946
Abnormal dreams 15.29 13.44 25 24516 8539 32480446
Congenital pigmentation disorder 15.28 13.44 3 24538 6 32488979
Genital herpes 15.24 13.44 8 24533 607 32488378
Atypical mycobacterial infection 15.12 13.44 9 24532 871 32488114
Psychiatric decompensation 15.11 13.44 11 24530 1495 32487490
CD4 lymphocytes abnormal 15.11 13.44 5 24536 116 32488869
Depression 15.10 13.44 125 24416 96935 32392050
Treatment failure 15.02 13.44 64 24477 39099 32449886
Segmented hyalinising vasculitis 14.94 13.44 4 24537 43 32488942
Inappropriate schedule of product administration 14.89 13.44 8 24533 45817 32443168
CSF virus identified 14.85 13.44 4 24537 44 32488941
Testicular mass 14.83 13.44 5 24536 123 32488862
Hepatitis D 14.69 13.44 4 24537 46 32488939
Haematocrit decreased 14.68 13.44 3 24538 31659 32457326
Gastrointestinal haemorrhage 14.65 13.44 27 24514 86855 32402130
Foetal death 14.54 13.44 6 24535 262 32488723
Skin test negative 14.54 13.44 4 24537 48 32488937
Folate deficiency 14.50 13.44 10 24531 1247 32487738
Ophthalmic herpes simplex 14.46 13.44 6 24535 266 32488719
Retinal telangiectasia 14.42 13.44 3 24538 9 32488976
Foetal monitoring abnormal 14.42 13.44 3 24538 9 32488976
Blood alkaline phosphatase increased 14.31 13.44 55 24486 32077 32456908
Secondary syphilis 14.24 13.44 4 24537 52 32488933
Reversible ischaemic neurological deficit 14.24 13.44 4 24537 52 32488933
Foetal cystic hygroma 14.18 13.44 3 24538 10 32488975
Viral load decreased 14.17 13.44 4 24537 53 32488932
International normalised ratio increased 13.94 13.44 10 24531 49025 32439960
Pancytopenia 13.93 13.44 117 24424 91118 32397867
Contusion 13.90 13.44 4 24537 33464 32455521
Therapeutic product effect incomplete 13.75 13.44 7 24534 41334 32447651
Transient neonatal pustular melanosis 13.75 13.44 3 24538 12 32488973
Congenital ureterocele 13.75 13.44 3 24538 12 32488973
Foetal growth restriction 13.67 13.44 16 24525 3996 32484989
Thrombosis 13.45 13.44 9 24532 45745 32443240

Pharmacologic Action:

SourceCodeDescription
ATC J05AF06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleoside and nucleotide reverse transcriptase inhibitors
ATC J05AR02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR13 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
FDA MoA N0000009947 Nucleoside Reverse Transcriptase Inhibitors
FDA EPC N0000175462 Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
MeSH PA D019380 Anti-HIV Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D044966 Anti-Retroviral Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
MeSH PA D018894 Reverse Transcriptase Inhibitors
FDA MoA N0000193954 Cytochrome P450 1A1 Inhibitors
CHEBI has role CHEBI:36044 anti-virus drug
CHEBI has role CHEBI:53756 reverse transcriptase inhibitor
CHEBI has role CHEBI:88188 allergenic drug

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Human immunodeficiency virus infection indication 86406008 DOID:526
Toxic amblyopia contraindication 965003
Myositis contraindication 26889001 DOID:633
Hepatic failure contraindication 59927004
Pancreatitis contraindication 75694006 DOID:4989
Large liver contraindication 80515008
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Disorder of muscle contraindication 129565002 DOID:423
Steatosis of liver contraindication 197321007
Acute pancreatitis contraindication 197456007 DOID:2913
Chronic pancreatitis contraindication 235494005
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Hypertriglyceridemia contraindication 302870006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001
Obesity contraindication 414916001 DOID:9970
HLA-B 5701 Positive Status contraindication
Drug Resistance to Anti-retroviral Therapy contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.09 acidic
pKa2 5.64 Basic
pKa3 0.88 Basic
pKa4 0.28 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Reverse transcriptase/RNaseH Enzyme INHIBITOR EC50 5.28 CHEMBL CHEMBL
Gag-Pol polyprotein Polyprotein EC50 5.28 WOMBAT-PK
Reverse transcriptase Enzyme IC50 6.89 CHEMBL

External reference:

IDSource
4029879 VUID
N0000180961 NUI
D00891 KEGG_DRUG
188062-50-2 SECONDARY_CAS_RN
190521 RXNORM
C0663655 UMLSCUI
CHEBI:421707 CHEBI
1KX PDB_CHEM_ID
CHEMBL1380 ChEMBL_ID
CHEMBL2106686 ChEMBL_ID
CHEMBL4303288 ChEMBL_ID
DB01048 DRUGBANK_ID
CHEMBL1200619 ChEMBL_ID
C106538 MESH_SUPPLEMENTAL_RECORD_UI
441300 PUBCHEM_CID
11152 IUPHAR_LIGAND_ID
7544 INN_ID
WR2TIP26VS UNII
14010 MMSL
191490 MMSL
30504 MMSL
66957 MMSL
7865 MMSL
d04376 MMSL
007687 NDDF
007688 NDDF
116084008 SNOMEDCT_US
387005008 SNOMEDCT_US
412074007 SNOMEDCT_US
4021139 VANDF
4024130 VANDF
4029879 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Abacavir HUMAN PRESCRIPTION DRUG LABEL 1 0121-0897 SOLUTION 20 mg ORAL ANDA 28 sections
Abacavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0378-4105 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
Abacavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6523 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
Abacavir HUMAN PRESCRIPTION DRUG LABEL 1 0904-6874 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
Abacavir Human Prescription Drug Label 1 31722-557 TABLET 300 mg ORAL ANDA 27 sections
Abacavir Human Prescription Drug Label 1 31722-562 SOLUTION 20 mg ORAL ANDA 28 sections
Abacavir and Lamivudine Human Prescription Drug Label 2 35573-402 TABLET, FILM COATED 600 mg ORAL ANDA 29 sections
Abacavir and Lamivudine Human Prescription Drug Label 2 35573-430 TABLET, FILM COATED 600 mg ORAL ANDA 27 sections
Abacavir and Lamivudine HUMAN PRESCRIPTION DRUG LABEL 2 42291-115 TABLET, FILM COATED 600 mg ORAL ANDA 28 sections
EPZICOM HUMAN PRESCRIPTION DRUG LABEL 2 49702-206 TABLET, FILM COATED 600 mg ORAL NDA 27 sections
TRIZIVIR HUMAN PRESCRIPTION DRUG LABEL 3 49702-217 TABLET, FILM COATED 300 mg ORAL NDA 26 sections
ZIAGEN HUMAN PRESCRIPTION DRUG LABEL 1 49702-221 TABLET, FILM COATED 300 mg ORAL NDA 26 sections
ZIAGEN HUMAN PRESCRIPTION DRUG LABEL 1 49702-222 SOLUTION 20 mg ORAL NDA 26 sections
Triumeq HUMAN PRESCRIPTION DRUG LABEL 3 49702-231 TABLET, FILM COATED 600 mg ORAL NDA 26 sections
Abacavir HUMAN PRESCRIPTION DRUG LABEL 1 50268-049 TABLET 300 mg ORAL ANDA 27 sections
Abacavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 51079-204 TABLET, FILM COATED 300 mg ORAL ANDA 29 sections
Abacavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 53808-0627 TABLET, FILM COATED 300 mg ORAL ANDA 30 sections
EPZICOM HUMAN PRESCRIPTION DRUG LABEL 2 53808-0767 TABLET, FILM COATED 600 mg ORAL NDA 26 sections
ZIAGEN HUMAN PRESCRIPTION DRUG LABEL 1 53808-0811 TABLET, FILM COATED 300 mg ORAL NDA 29 sections
TRIZIVIR HUMAN PRESCRIPTION DRUG LABEL 3 53808-0990 TABLET, FILM COATED 300 mg ORAL NDA 28 sections
EPZICOM HUMAN PRESCRIPTION DRUG LABEL 2 54868-5600 TABLET, FILM COATED 600 mg ORAL NDA 26 sections
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE HUMAN PRESCRIPTION DRUG LABEL 3 57297-286 TABLET 300 mg ORAL ANDA 29 sections
Abacavir HUMAN PRESCRIPTION DRUG LABEL 1 64380-717 TABLET 300 1 ORAL ANDA 25 sections
Abacavir Human Prescription Drug Label 1 64980-405 SOLUTION 20 mg ORAL ANDA 27 sections
Abacavir Human Prescription Drug Label 1 65862-073 TABLET, FILM COATED 300 mg ORAL ANDA 27 sections
Abacavir Human Prescription Drug Label 1 65862-089 SOLUTION 20 mg ORAL ANDA 27 sections
Abacavir and Lamivudine Human Prescription Drug Label 2 65862-335 TABLET, FILM COATED 600 mg ORAL ANDA 28 sections
Abacavir HUMAN PRESCRIPTION DRUG LABEL 1 68084-021 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
ABACAVIR, LAMIVUDINE AND ZIDOVUDINE HUMAN PRESCRIPTION DRUG LABEL 3 68180-286 TABLET 300 mg ORAL ANDA 28 sections
Abacavir and Lamivudine HUMAN PRESCRIPTION DRUG LABEL 2 68180-288 TABLET, FILM COATED 600 mg ORAL ANDA 26 sections